FAKTOR OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - BOERSE MUENCHEN 01:16:17 25/05/2024 am IST | ||
| 8.66 EUR | -3.99% |
|
| Current month | -36.97% | ||
| 1 month | -33.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 8.66 | -3.99% |
| 23/24/23 | 9.02 | -2.38% |
| 22/24/22 | 9.24 | -3.85% |
| 21/24/21 | 9.61 | +4.46% |
| 20/24/20 | 9.2 | -1.18% |
Real-time BOERSE MUENCHEN
Last update May 25, 2024 at 01:16 am IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD33LE |
| ISIN | DE000HD33LE4 |
| Date issued | 27/02/2024 |
| Strike | 601.1 $ |
| Maturity | Unlimited |
| Parity | 16.02 : 1 |
| Emission price | 10.27 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.23 € |
|---|---|
| Lowest since issue | 8.66 € |
| Spread | 0.01 € |
| Spread % | 0.12% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
457
USD
Average target price
462.8
USD
Spread / Average Target
+1.28%
- Stock Market
- Certificates
- Certificat
